27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat ("ENT") conditions, today announced that management will participate in the following upcoming investor conferences:
- Berenberg US CEO Conference 2020
Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at 2:00 p.m. ET / 11:00 am PT on Thursday, November 12, 2020.
A live webcast of the fireside chat at the Berenberg US CEO Conference 2020 can be accessed by visiting the "Investor Relations" page of the Company's website at www.intersectENT.com. A replay will be available on the Company's website following the event. Canaccord Genuity Virtual MedTech & Diagnostics Forum
Management will participate in investor 1x1 meetings on Thursday, November 19, 2020.- Piper Sandler 32nd Annual Virtual Healthcare Conference
Management will participate in investor 1x1 meetings on Wednesday, December 2, 2020.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
About Intersect ENT
Intersect ENT is a company transforming care for patients with ear, nose and throat conditions. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.
For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.
Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105006138/en/
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.